Lim SM - Search Results

1

Path Less Traveled: Targeting Rare Driver Oncogenes in Non-Small-Cell Lung Cancer.

Lim SM, Lee JB, Oya Y, Nutzinger J, Soo R. Lim SM, et al. JCO Oncol Pract. 2024 Jan;20(1):47-56. doi: 10.1200/OP.23.00273. Epub 2023 Sep 21. JCO Oncol Pract. 2024. PMID: 37733983 Review.

2

Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer.

Lim SM, Chang H, Cha YJ, Liang S, Tai YC, Li G, Pestova E, Policht F, Perez T, Soo RA, Park WY, Kim HR, Shim HS, Cho BC. Lim SM, et al. Lung Cancer. 2017 Sep;111:79-83. doi: 10.1016/j.lungcan.2017.07.016. Epub 2017 Jul 12. Lung Cancer. 2017. PMID: 28838404

3

Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.

Soo RA, Lim SM, Syn NL, Teng R, Soong R, Mok TSK, Cho BC. Soo RA, et al. Among authors: lim sm. Lung Cancer. 2018 Jan;115:12-20. doi: 10.1016/j.lungcan.2017.11.009. Epub 2017 Nov 13. Lung Cancer. 2018. PMID: 29290252 Review.

4

Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies.

Lim SM, Syn NL, Cho BC, Soo RA. Lim SM, et al. Cancer Treat Rev. 2018 Apr;65:1-10. doi: 10.1016/j.ctrv.2018.02.006. Epub 2018 Feb 20. Cancer Treat Rev. 2018. PMID: 29477930 Review.

5

Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors.

Yun MR, Lim SM, Kim SK, Choi HM, Pyo KH, Kim SK, Lee JM, Lee YW, Choi JW, Kim HR, Hong MH, Haam K, Huh N, Kim JH, Kim YS, Shim HS, Soo RA, Shih JY, Yang JC, Kim M, Cho BC. Yun MR, et al. Among authors: lim sm. Cancer Res. 2018 Jun 15;78(12):3350-3362. doi: 10.1158/0008-5472.CAN-17-3146. Epub 2018 Apr 18. Cancer Res. 2018. PMID: 29669761

6

Can We Prevent Resistance to Osimertinib? Combination or Sequential.

Kim MH, Lim SM, Lee K, Soo RA, Cho BC. Kim MH, et al. Among authors: lim sm. J Thorac Oncol. 2018 Jul;13(7):877-879. doi: 10.1016/j.jtho.2018.05.012. J Thorac Oncol. 2018. PMID: 29935843 Free article. No abstract available.

7

The promise of bispecific antibodies: Clinical applications and challenges.

Lim SM, Pyo KH, Soo RA, Cho BC. Lim SM, et al. Cancer Treat Rev. 2021 Sep;99:102240. doi: 10.1016/j.ctrv.2021.102240. Epub 2021 Jun 4. Cancer Treat Rev. 2021. PMID: 34119803 Review.

8

Patritumab Deruxtecan: Paving the Way for EGFR-TKI-Resistant NSCLC.

Lim SM, Kim CG, Lee JB, Cho BC. Lim SM, et al. Cancer Discov. 2022 Jan;12(1):16-19. doi: 10.1158/2159-8290.CD-21-1429. Cancer Discov. 2022. PMID: 35022206

9

Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity.

Lee W, Kim DK, Synn CB, Lee HK, Park S, Jung DS, Choi Y, Kim JH, Byeon Y, Kim YS, Lee S, Lee S, Joo Y, Lee EJ, Yun MR, Heo SG, Yang W, Jung JE, Kim EK, Park J, Park JD, Lee DJ, Kim HW, Lim SM, Hong MH, Ahn BC, Lee JB, Pyo KH. Lee W, et al. Among authors: lim sm. Front Oncol. 2022 Mar 9;12:821391. doi: 10.3389/fonc.2022.821391. eCollection 2022. Front Oncol. 2022. PMID: 35356198 Free PMC article.

10

Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer.

Lee J, Piotrowska Z, Soo R, Cho BC, Lim SM. Lee J, et al. Among authors: lim sm. Ther Adv Med Oncol. 2022 Dec 17;14:17588359221144099. doi: 10.1177/17588359221144099. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 36544540 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

947 results

Search Page

Filters